



The Lupus Research Alliance unites the global lupus community in bold determination to free the world of lupus through the power of science.

We will transform the lives of people affected by lupus as we welcome and embrace a new scientific era, pioneer innovation, push the frontiers of knowledge, enlist diverse new scientific talent, and lead the drive to new treatments, prevention and cure.

ONE OF THE MOST TRUSTWORTHY HEALTH ORGANIZATIONS IN THE COUNTRY

The Lupus Research Alliance (LRA) was once again named by *Consumer Reports* as one of the best health organizations to donate to in 2021. This blue-chip recognition is based on ratings by independent watchdog groups like BBB Wise Giving Alliance and CharityWatch.

We have invested more than \$215 million in lupus research programs and delivered breakthroughs that are speeding up the development of new treatments and enabling scientists to investigate theories toward prevention and the ultimate goal – a cure.

PUSHING THE BOUNDARIES OF LUPUS RESEARCH

The LRA forged ahead in 2021, making great strides in the advancement of lupus research – despite the many obstacles that the Covid-19 pandemic continued to present to our scientific community, supporters, and volunteers.

Taking a multi-faceted approach to understanding lupus at the molecular level, the LRA awarded a number of trailblazing investigations conducted by many of the world's most brilliant scientists and junior underrepresented minority researchers in the field of lupus research with more than \$9,921,000 million in funding.

The following is a sampling of the extraordinary work that was funded by the LRA in 2021.

- In September, we announced the inaugural recipients of the LRA's largest grant to date – the **Global Team Science Award**. We will fund international, multidisciplinary research teams to unravel lupus heterogeneity (how much the disease varies from one person to another) with the aim of discovering new avenues to personalized treatment approaches. Two awards of \$3 million each will support the research projects of two teams of extraordinary investigators led by the renowned leaders in the lupus field – Virginia Pascual, MD, Weill Cornell Medicine and Ignacio Sanz, MD, Emory University – to bring their groundbreaking research concepts to fruition.
- \$500,000 was granted through the **Distinguished Innovator Award (DIA)** to Nir Hacohen, PhD, Harvard University. Dr. Hacohen has made significant headway in identifying the many cell types that play a role in the development of lupus nephritis.
- In June, the LRA announced that Martin Kriegel MD, PhD, University of Münster, is the **2021 Lupus Insight Prize Awardee** for his cutting-edge research on gut microbiome as a trigger for lupus. Dr. Kriegel received \$100,000 to advance his discovery of a particular organism that can break through the gut lining of people with lupus.
- Eleven exceptional scientists received the **Lupus Innovation Award** at the end of 2021. Three of these investigators have chosen to study the genetic causes of lupus and the other eight aim to develop personalized medicine for lupus patients – either by maximizing the effectiveness of existing immunosuppressive drugs or by laying the foundation for brand-new therapeutics.

BOARD OF DIRECTORS

Ira Akselrad
Co-Chairman
Richard K. DeScherer
Co-Chairman
Brenda Blackmon
Secretary
Joseph Mauriello
Treasurer
Bishop Rudy V. Carlton
William "Willie" Colon
Thomas O. Daniel, MD
Jennie L. DeScherer
Katey Driscoll
Sir Marc Feldmann FRS
Moti Ferder
Anna Fisch
Joe Germanotta
David M. Kies
Daniel M. LaVecchia
Veronica Vargas Lupo
Molly McCabe
Nadeem Meghji
William J. Mulvihill
Robert Seder, MD
Daniel J. Wallace, MD,
FACP, MACR
Carol Weisman
Julius Williams
William J. Wolfe
Spencer Zwick

OFFICERS

Kenneth M. Farber
President & CEO
Debra Rose
Chief Finance & Administrative Officer
Teodora Staeva, PhD
Chief Scientific Officer
Andrea J. O'Neill
Executive Director
Albert Roy
Executive Director, Lupus Therapeutics, LLC

SCIENTIFIC ADVISORY BOARD

Gary A. Koretzky, MD, PhD
Chair
Andy Chan, MD, PhD
Mary Collins, PhD
Judith James, MD, PhD
Josef Penninger, MD, PhD
David J. Rawlings, MD
Jane Salmon, MD
Jason Williams



POWER IN NUMBERS

If there is one thing that the Lupus Research Alliance has learned, it's that there is power in numbers, and we need no greater proof than our Walk with Us to Cure Lupus program.

Walkers – passionate about ending lupus – may walk because a family member, friend or colleague has lupus. Or they may walk because they have lupus themselves. The important part is they decided to be part of the solution – even virtually! People around the country were resolute in participating in the LRA Virtual Walk program to ensure better treatments and eventually a cure become a reality for lupus patients around the world. Such passion has generated over \$1.2 million for 2021. Even more remarkable is the fact that since this grassroots fundraiser began, a cumulative total of over \$42.5 million has been raised for critical lupus initiatives from these supporters.

We extend our sincere gratitude and appreciation to our Board of Directors, who fund all our administration and fundraising expenses. Their ongoing generosity allows us to commit 100% of all other donations to support lupus research programs.

The following is an overview of the Lupus Research Alliance's income and expenditures for the fiscal year ended December 31, 2021.

Revenue & Other Support:

Contributions	\$ 18,941,837
Other Support	\$ 7,072,076

Total Revenue & Other Support: \$26,013,913

Program Expenditures:

Research	\$ 11,693,925
Scientific programs	\$ 9,253,814
Public policy	\$ 647,293

Total Program Expenditures: \$21,595,032


Administration Expenditures: \$ 2,174,307 ★

Fundraising Expenditures: \$ 2,778,881 ★

End of Year Net Asset Balance: \$69,486,118

*The LRA's Supporting Services are covered by donations from its Board of Directors

Because the LRA Board of Directors funds our administrative and fundraising costs, 100% of your contribution to the LRA goes directly to support lupus research programs.



The LRA contracts Lutz and Carr, CPA's as its independent auditor. A complete copy of the audited financial statements of the LRA for the year ended December 31, 2021, together with the independent auditor's report thereon, may be obtained through a written request to the LRA's national office and is also available on the LRA website; lupusresearch.org. The LRA is tax-exempt under 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible to the extent allowed by law.



270 Madison Avenue, Suite 300
New York, NY 10016